Inhibikase Therapeutics (IKT) Accounts Payables (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Accounts Payables for 7 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables fell 6.19% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 6.19% YoY), while the FY2025 annual figure was $1.2 million, up 22.8% from the prior year.
• Accounts Payables climbed to $1.6 million in Q1 2026 per IKT's latest filing, from $1.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $21.8 million in Q1 2023 and bottomed at $620528.0 in Q3 2025.
• Historically, Accounts Payables has averaged $2.9 million across 5 years, with a median of $1.3 million in 2024.
• On a YoY basis, Accounts Payables climbed as much as 2599.29% in 2023 and fell as far as 83.21% in 2023.
• Inhibikase Therapeutics' Accounts Payables stood at $1.2 million in 2022, then tumbled by 43.82% to $646767.0 in 2023, then soared by 45.81% to $943019.0 in 2024, then rose by 22.8% to $1.2 million in 2025, then jumped by 37.07% to $1.6 million in 2026.
• Business Quant data shows IKT's Accounts Payables at $1.6 million in Q1 2026, $1.2 million in Q4 2025, and $620528.0 in Q3 2025.